Fundraising Fox

Joël Jean-Mairet

Investor

Managing Partner at Ysios Capital

Barcelona, Catalonia, Spain

Writes $1M – $7.5M checks · typically $1M

About

Joël Jean-Mairet is Managing Partner at Ysios Capital, where he oversees management, strategy and day-to-day operations. In 2001 he co-founded Glycart Biotechnology and served as its CEO until its sale to F. Hoffmann-La Roche four years later; Glycart originated the anti-CD20 antibody obinutuzumab/Gazyva. He holds an MSc in Biotechnology and a PhD in Cell Biology and Immunotherapeutics, both from ETH Zürich.

LinkedIn ↗

Invests in

Biotech

Experience

  1. Ysios CapitalManaging Partner and co-Foundercurrent2007 — presentBarcelona
  2. ONA TherapeuticsDirectorcurrent2020 — presentBarcelona, Catalonia, Spain
  3. Inbiomotion S.L.Chairman of the Boardcurrent2012 — presentGreater Barcelona Metropolitan Area
  4. AM-PharmaBoard Observercurrent2019 — presentUtrecht, Netherlands
  5. AdcendoDirector2021 — 2024Copenhagen Municipality, Capital Region of Denmark, Denmark
  6. Mineralys Therapeutics, Inc.Board observer2022 — 2023
  7. Splice BioDirector2020 — 2023Barcelona, Catalonia, Spain
  8. Lava Therapeutics B.V. (NASDAQ: LAVA)Director2020 — 2022Utrecht, Netherlands
  9. Sanifit Laboratoris (now CSL)Director2015 — 2022
  10. Aura Biosciences (NASDAQ: AURA)Director2015 — 2021
  11. Rainier Therapeutics (now Fusion Pharmaceuticals - NASDAQ: FUSN)Director2017 — 2020San Francisco
  12. AM-Pharma B.V.Director2011 — 2019
  13. Medlumics S.L.Director2011 — 2017Madrid
  14. Dermalumics S.L.Director2014 — 2017Greater Madrid Metropolitan Area
  15. Tigenix N.V. (now Takeda Pharmaceuticals)Director2011 — 2013
  16. Biovex Inc (now Amgen)Board observer2009 — 2011
  17. Cellerix S.A. (now Takeda Pharmaceuticals)Chairman of the Board2007 — 2011Greater Madrid Metropolitan Area
  18. GLYCART Biotechnology AG (since 2005 Roche)CEO and co-founder2001 — 2006

Education

  1. Eidgenössische Technische Hochschule ZürichPhD, MSc, Biotechnology, Cell Biology, Therapeutic Antibodies1996 — 2001

Skills & more

Biotechnology65Drug Discovery13Due Diligence9Entrepreneurship23Mergers2Oncology8Start-ups37Strategy17Technology Transfer32Venture Capital75Venture Financing7Restructuring2
+12 moreRBiopharmaceuticalsBusiness StrategyClinical DevelopmentCommercializationCorporate DevelopmentCorporate FinanceDrug DevelopmentFDAInnovation ManagementInvestmentsLicensing

From Joël's professional profile.

Shared employers

Also worked at ONA Therapeutics5

Clara CampàsCo-founder and managing partner at Asabys PartnersGuillem MasferrerPartner at Asabys PartnersMontse VendrellPartner at Asabys PartnersPamela KleinVenture Partner at Ysios CapitalJose MesaPartner at Columbus Venture Partners

Also worked at AM-Pharma3

Andrea van ElsasInvestor at Third Rock VenturesKlaus BreinerManaging Partner at Pureos BioventuresMarkwin VeldersAdvisory Committee member at Curie Capital

Also worked at Adcendo5

Laura ArgelichAssociate at Ysios CapitalCarl KilanderPartner at HealthCapSamy RamadaneAnalyst at Atlas VentureMarten SteenManaging Partner at HealthCapDan MarksPrincipal at RA Capital

Also worked at Mineralys Therapeutics, Inc.2

Derek DiRoccoPartner at RA CapitalHeather BehannaPrincipal at SR One Capital Management

Investments

Board seats

AdcendoAM-PharmaAura BiosciencesInbiomotionLAVA TherapeuticsMedLumicsOna TherapeuticsSanifit TherapeuticsSplice Bio

Per the firm's website.

Colleagues at Ysios Capital

Almudena Méndez
Associate at Ysios Capital
Antoni Ribas
Venture Partner at Ysios Capital
Arturo Urrios
Partner at Ysios Capital
Carlos Garcia-Echeverria
Venture Partner at Ysios Capital
Carlos Paya
Venture Partner at Ysios Capital
Catalina Cuchy
Executive Assistant at Ysios Capital
Cristina Garmendia
General Partner at Ysios Capital
David L. Lacey
Venture Partner at Ysios Capital

Network2

Carole Nuechterlein
Head of Roche Venture Fund at Roche Venture Fund
Cristina Garmendia
General Partner at Ysios Capital

Investors connected to Joël in public investor directories — a warm-intro map.